Wolverine Asset Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$269 Buy
+1,344
New +$384 ﹤0.01% 1697
2026
Q1
– Sell
-16,223
Closed -$48K – 1762
2025
Q4
$48K Sell
16,223
-43,208
-73% -$98.6K ﹤0.01% 1283
2025
Q3
$42.2K Buy
+59,431
New +$45K ﹤0.01% 1213
2025
Q1
– Sell
-15,889
Closed -$13.4K – 1625
2024
Q4
$13.4K Buy
+15,889
New +$23.5K ﹤0.01% 1328
2024
Q3
– Sell
-28,197
Closed -$33.6K – 1687
2024
Q2
$33.6K Buy
28,197
+15,507
+122% +$49.6K ﹤0.01% 1208
2024
Q1
$66K Buy
12,690
+7,057
+125% +$21.5K ﹤0.01% 1087
2023
Q4
$4.79K Buy
+5,633
New +$4.33K ﹤0.01% 1475

Other funds holding ENGNW

Wolverine Asset Management's ENGNW Position: Q3 2026 in Review

Wolverine Asset Management opened a new position in enGene Therapeutics Warrants (ENGNW) in Q3 2026: 1,344 shares worth $269. The stake represents ﹤0.01% of the portfolio and ranks #1697 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in ENGNW as recently as Q4 2025.

Wolverine Asset Management first reported a position in ENGNW in Q4 2023 and has held it in 7 quarters since. The position peaked at $66K in Q1 2024. 2 funds tracked by Wall St. Rank hold ENGNW as of Q3 2026.

  • Wolverine Asset Management held 1,344 shares of enGene Therapeutics Warrants worth $269 as of Q3 2026.
  • enGene Therapeutics Warrants was a new Wolverine Asset Management position in Q3 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of Wolverine Asset Management's portfolio in Q3 2026, its #1697 holding.
  • Wolverine Asset Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 7 quarters since.
  • Wolverine Asset Management's enGene Therapeutics Warrants position peaked at $66K in Q1 2024.
  • 2 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q3 2026.

Based on Wolverine Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.